Trial Profile
Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Lenvatinib (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer; Carcinoma
- Focus Therapeutic Use
- 01 Apr 2022 Results published in the Clinical Cancer Research
- 30 Sep 2020 Planned End Date changed from 1 Jun 2018 to 1 Jun 2021.
- 30 Sep 2020 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2021.